Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

FZ-A038

Catalog No. T9901A-490 Copy Product Info
🥰Excellent
FZ-A038 is a humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3). DLL3 is specifically overexpressed in small cell lung cancer (SCLC) and neuroendocrine carcinomas, with its signaling activation involving proteolytic cleavage by Gamma-secretase. FZ-A038 binds to the extracellular domain of DLL3 with high affinity and induces rapid internalization. As the antibody component of the antibody-drug conjugate (ADC) FZ-AD005, it delivers a conjugated Topoisomerase I inhibitor (an exatecan derivative) into tumor cells via internalization, inducing DNA damage and exerting potent anti-tumor activity.

FZ-A038

Copy Product Info
🥰Excellent
Catalog No. T9901A-490

FZ-A038 is a humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3). DLL3 is specifically overexpressed in small cell lung cancer (SCLC) and neuroendocrine carcinomas, with its signaling activation involving proteolytic cleavage by Gamma-secretase. FZ-A038 binds to the extracellular domain of DLL3 with high affinity and induces rapid internalization. As the antibody component of the antibody-drug conjugate (ADC) FZ-AD005, it delivers a conjugated Topoisomerase I inhibitor (an exatecan derivative) into tumor cells via internalization, inducing DNA damage and exerting potent anti-tumor activity.

FZ-A038
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
FZ-A038 is a humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3). DLL3 is specifically overexpressed in small cell lung cancer (SCLC) and neuroendocrine carcinomas, with its signaling activation involving proteolytic cleavage by Gamma-secretase. FZ-A038 binds to the extracellular domain of DLL3 with high affinity and induces rapid internalization. As the antibody component of the antibody-drug conjugate (ADC) FZ-AD005, it delivers a conjugated Topoisomerase I inhibitor (an exatecan derivative) into tumor cells via internalization, inducing DNA damage and exerting potent anti-tumor activity.
In vitro
FZ-A038 binds human DLL3 with high affinity and specificity, undergoing rapid internalization in NCI-H69 and NCI-H187 cells. In ADC format (FZ-AD005), it exhibits potent cytotoxicity (sub-nanomolar IC50) by inducing DNA double-strand breaks and subsequent apoptosis in DLL3+ tumor cells [1].
In vivo
In pharmacological studies using SCLC and neuroendocrine carcinoma xenograft mouse models, systemic administration of the FZ-AD005 ADC (containing the FZ-A038 arm) results in significant and durable tumor regression [1].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetDLL3
Chemical Properties
Antibody Information
IsotypeIgG1-LFLE-PS
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy FZ-A038 | purchase FZ-A038 | FZ-A038 cost | order FZ-A038 | FZ-A038 in vivo | FZ-A038 in vitro